Navigation Links
Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products
Date:10/26/2012

AUSTIN, Texas, Oct. 26, 2012 /PRNewswire/ -- Altogen Labs announced the filing of a patent for bioremediation microorganism isolation and selection methods (USPTO application 13/490,508). This environmental technology is based on isolation of naturally present microorganisms in heavily contaminated soil, which allows accelerating natural bioremediation processes. We don't have to wait hundreds of years for nature to degrade an oil spill or clean up land contaminated with toxic chemicals and carcinogens. Instead, by reintroducing natural bacteria to oil spill sites, Altogen Labs accomplish oil degradation process in just a few months. This bioaugmentation platform technology to remediate crude oil and chemical spills can be applied worldwide.

Both laboratory and field tests showed that Altogen Labs site-specific bacterial strains are highly effective for remediation of crude oil- and petroleum-saturated earth. The bacteria is grown in the lab to speed up the natural process and then re-introduced to the contaminated site. Multiple lab studies show that after consuming the oil and having no remaining food source, the bacteria die. No adverse effects of using the live bacteria have been observed, and the effectiveness and safety of the method are remarkable. Scientists at Altogen Labs used functional genomics to perform whole genome sequencing study to characterize these newly identified natural microorganisms and identify specific biosurfactant and quorum-sensing genes that allow the microorganisms to work together for efficient and effective crude oil spill bioremediation.

Altogen Labs also offers soil remediation services and development programs focused on other chemical contaminations besides crude oil, including remediation of soil with recalcitrant organic chemical spills including polycyclic aromatic hydrocarbons, petroleum, pesticides, herbicides, perchlorate, carbon tetrachloride, chloroform, acetone, benzene, toluene, xylenes, perchloroethylene, chlorofluorocarbon, aliphatic chlorinated hydrocarbons, and other industrial and chemical manufacturing wastes and spills.

Altogen Labs announced that site-specific bioremediation products will be manufactured and sold through its exclusive distributor - Soil Bioremediation Inc (www.soil-bio-remediation.com) located in Austin, Texas.

About Altogen Labs

Altogen Labs (www.altogenlabs.com) is GLP compliant laboratory that provides biotechnology research services and biology CRO services to pharmaceutical, biotechnology, and academic institutions worldwide. Bioremediation is one of the company's focus areas. This bioaugmentation-based soil remediation technology provides conversion of toxic, environment-contaminating compounds into innocuous substances by using natural oil-degrading bacteria.

Contact
Altogen Labs
4020 South Industrial Dr, Suite 130
Austin TX 78744 USA
(512) 433-6177
Web: www.altogenlabs.com
E-mail: info@altogenlabs.com


'/>"/>
SOURCE Altogen Labs
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... ... microbiome and improve efficiency of livestock farming while reducing the use of antibiotics ... additional intellectual property from Cornell University. , These new proprietary technologies expand ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... stock market news outlet had initiated coverage on Interpace Diagnostics. Interpace Diagnostics ... identifies exposure, progression and risk analysis from specific cancers in humans. , ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health , a ... full advisory board. The board comprises leaders spanning business, technology, academia, and pharmaceutical ... VP of Engineering, to Chief Technology Officer. Crooks will lead strategy and development ...
(Date:7/20/2017)... , ... July 20, 2017 , ... Corporate Directors Forum ... its 27th annual Director of the Year Awards. , The awards will be presented ... This annual event celebrates directors who have made significantly positive contributions in the ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
Breaking Biology News(10 mins):